A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
Clinical trial NCT04954456 · UNKNOWN
Trial details
- NCT number
- NCT04954456
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-02
- Primary completion
- 2022-12-30
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.